Factors Predicting Compliance with Palivizumab in High-Risk Infants

ABSTRACT

Palivizumab must be administered monthly by intramuscular injection throughout the RSV season to maintain the serum concentration at a level sufficient to provide protection against respiratory syncytial virus (RSV). The objective of this study is to determine factors associated with completing all doses of palivizumab. The method was a survey mailed to the families of 385 high-risk children who were eligible to receive palivizumab at Columbus Children's Hospital in 1998-1999. Seventy-eight percent of eligible children received all doses of palivizumab. The strongest predictor of compliance was parents' perception that palivizumab would protect their child from RSV; 67% of parents in the compliant group reported they believed palivizumab protected their child ``a great deal'' against RSV compared with 48% in the noncompliant group (p = 0.04). Difficulty with transportation was also a barrier to compliance; 85% of parents in the compliant group reported no difficulty with transportation compared with 65% in the non-compliant group (p = 0.004). An interaction between Medicaid status and parental worry showed that parents whose child received Medicaid and who worried a lot (about their child getting RSV) were more likely to be compliant (Odds ratio = 6.62, p = 0.03). Communication with parents that focuses on the benefit of palivizumab in reducing RSV-associated illness and hospitalizations may increase compliance.

KEYWORD

Compliance - premature - low birth weight - respiratory syncytial virus - prevention

REFERENCES

• 1 Hall C B, McCarthy C A. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases 5th ed. Philadelphia: Churchill Livingstone; 2000;0:1782-1801
• 2 Groothius J R, Gutierrez K M, Lauer B A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.  Pediatrics . 1988;  82 199-203
• 3 Cunningham C K, McMillan J A, Gross S J. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation.  Pediatrics . 1991;  88 527-532
• 4 Joffe S, Escobar G J, Black S B, Armstrong M A, Lieu T A. Rehospitalization for Respiratory Syncytial Virus among premature infants.  Pediatrics . 1999;  104 894-899
• 5 The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.  Pediatrics . 1998;  102 531-537
• 6 Subramanian S KN, Weisman L E, Rhodes T. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia.  Pediatr Infect Dis J . 1998;  17 110-115
• 7 American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG.  Pediatrics . 1998;  102 1211-1216
• 8 Stevens T P, Sinkin R A, Hall C B, Maniscalco W M, McConnochie K M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier.  Arch Pediatr Adolesc Med . 2000;  154 55-61
• 9 Hall C B, Stevens T P, Swantz R J, Sinkin R A, McBride J T. Development of local guidelines for prevention of respiratory syncytial viral infections.  Pediatr Infect Dis J . 1999;  18 850-853
• 10 Joffe S, Ray G T, Escobar G J, Black S B, Lieu T A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.  Pediatrics . 1999;  104 419-427
• 11 Becker M H, Maiman L A. Sociobehavioral determinants of compliance with health and medical care recommendations.  Med Care . 1975;  13 10-24
• 12 Janz N K, Becker M H. The health belief model: a decade later.  Health Educ Q . 1984;  11 1-47
• 13 Becker M H, Drachman R H, Kirscht J P. Predicting mothers' compliance with pediatric medical regimens.  J Pediatr . 1972;  81 843-854
• 14 Valdez R B, Ware J E, Manning W G. Prepaid group practice effects on the utilization of medical services and health outcomes for children: results from a controlled trial.  Pediatrics . 1989;  83 168-180
• 15 Szilagyi P G, Rodewald L E, Sauageau J, Yoos L, Doane C. Improving influenza vaccination rates in children with asthma: a test of a computerized reminder system and an analysis of factors predicting vaccination compliance.  Pediatrics . 1992;  90 871-875
• 16 DeVellis R F. Factor analytic strategies. In: Scale Development: Theory and Applications London: Sage Publications 1991: 91-109
• 17 SPSS Release 10.0. Chicago: SPSS Inc.; 1999
• 18 Ball L K, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication.  Pediatrics . 1998;  101 453-458
• 19 Taylor J A, Darden P M, Slora E, Hasemeier C M, Asmussen L, Wasserman R. The influence of provider behavior, parental characteristics, and a public policy initiative on the immunization status of children followed by private pediatricians: a study from pediatric research in office settings.  Pediatrics . 1997;  99 209-215
• 20 Meszaros J R, Asch D A, Baron J, Hershey J C, Kunreuther H, Schwartz-Buzaglo J. Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children.  J Clin Epidemiol . 1996;  49 697-703
• 21 Tuerrsky A, Kahneman D. The framing of decisions and the psychology of choice.  Science . 1981;  211 453-458
• 22 Rothman A J, Salovey P. Shaping perceptions to motivate healthy behavior: the role of message framing.  Psychol Bull . 1997;  121 3-19